Citation Impact
Citing Papers
Immunological aspects of cancer chemotherapy
2007
Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence
2006
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
2018 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Parenteral Anticoagulants
2012 Standout
CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
2015
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Pulmonary Embolism
1998
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty
2001
The risk of venous thromboembolism is increased throughout the course of malignant glioma
2000
Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism
2000
Anticoagulation for patients with cancer and central venous catheters
2011
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
High Affinity Ca2+-binding Site in the Serine Protease Domain of Human Factor VIIa and Its Role in Tissue Factor Binding and Development of Catalytic Activity
1995
Low Molecular Weight Heparin
1997
Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis
2003 Standout
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
2001
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia
1996
Comparison of the Use of a Foot Pump with the Use of Low-Molecular-Weight Heparin for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. A Prospective, Randomized Trial*
1998
IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia
2017
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>
2002
Antithrombotic Therapy for VTE Disease
2016 Standout
Evidence‐based risk factors for postoperative deep vein thrombosis
2004
The Effect of Race and Sex on Physicians' Recommendations for Cardiac Catheterization
1999 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Rationale for Low-molecular-weight Heparin Prophylaxis after Total Knee Arthroplasty
2006
Esophageal Cancer
2003 Standout
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Severe Sepsis and Septic Shock
2013 Standout
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis
2005
Prevention of VTE in Nonsurgical Patients
2012 Standout
Cardiovascular Health and Disease in Women
1993
Comprehensive Deep Venous Thrombosis Prevention Strategy After Total-Knee Arthroplasty
2003
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
2004
Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease
2004
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Postthrombotic Syndrome After Hip or Knee Arthroplasty
2000
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
2005
Prospective Comparison of Contrast-Enhanced Computed Tomography Versus Magnetic Resonance Venography in the Detection of Occult Deep Pelvic Vein Thrombosis in Patients with Pelvic and Acetabular Fractures
2002
Executive Summary
2012 Standout
Use of Antithrombotic Agents During Pregnancy
2004
Cell biology of tissue factor, the principal initiator of blood coagulation
1996
Anticoagulation for patients with cancer and central venous catheters
2011
The Antiphospholipid Syndrome
2002 Standout
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Autoimmune heparin‐induced thrombocytopenia
2017
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients
2001
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
2000
Malignant Gliomas in Adults
2008 Standout
Prevention of Venous Thromboembolism
2004 Standout
Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome
2006
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement
2000
Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement
2001
Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip Replacement
1996
Hemostatic alterations in cancer patients
1992
Effect of Study Setting on Anticoagulation Control
2006
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
Prevention of Venous Thromboembolism
2008 Standout
Heparin‐induced thrombocytopenia: An international assessment of the quality of laboratory testing
2019
A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry
1994
Disseminated Intravascular Coagulation
1999 Standout
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
2012
Surveillance for Venous Thromboembolic Disease After Total Knee Arthroplasty
2001
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
1996 Nature
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters
2007
Deep vein thrombosis
2005
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
1994 Standout
Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer
2002
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
2003
The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin<subtitle>A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty</subtitle>
1998
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
1997
Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta‐analysis
2004
Chemotherapy-induced thrombosis
2006
Prevention of Venous Thromboembolism
1998
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Low Accuracy of Color Doppler Ultrasound in the Detection of Proximal Leg Vein Thrombosis in Asymptomatic High-Risk Patients
1992
1 Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology
1997
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Targeted CML therapy: controlling drug resistance, seeking cure
2005
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
2002 Standout
Deep vein thrombosis associated with central venous catheters – a review
2005
Medical Perspective Antiphospholipid Antibodies, Thrombosis and Atherosclerosis in Systemic Lupus Erythematosus: a Unifying 'Membrane Stress Syndrome' Hypothesis
1994
Low Molecular Weight Heparin
1997
Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL− Tumors
2008
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Users' Guides to the Medical Literature
1994 Standout
High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin‐induced thrombocytopenia antibodies
2013
State-of the-Art Review : Prevention of Thrombosis in Gynecologic Malignancy
1998
Venous Thromboembolism and Cancer: Risks and Outcomes
2003
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY
2005
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer
2006
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
2006
Functions of Ceramide in Coordinating Cellular Responses to Stress
1996 StandoutScience
Prevention of deep-vein thrombosis after total knee replacement
1999
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
2000
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
2002
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Noninvasive Diagnosis of Deep Venous Thrombosis
1998
Use of Antithrombotic Agents During Pregnancy
2001
Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty
1998
Use of Antithrombotic Agents During Pregnancy
1995
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Low-Molecular-Weight Heparins
1997 Standout
The Effects of Low-intensity Warfarin on Coagulation Activation in Patients with Antiphospholipid Antibodies and Systemic Lupus Erythematosus
1999
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement
2000
Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement
2000
Tumors: Wounds That Do Not Heal
1986 Standout
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy
2000
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Transient intermittent lymphocyte activation is responsible for the instability of angina.
1992
Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis
1997
Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture
1996
Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2005
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Thromboembolism in Hospitalized Neutropenic Cancer Patients
2006
Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?
2003
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of Robert Bona being referenced
Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus
1995
Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels
1990
The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor
1992
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2012
Thrombotic Complications of Central Venous Catheters in Cancer Patients
1999
Venous thrombosis in patients who have undergone major hip or knee surgery: detection with compression US and impedance plethysmography.
1991
Central line thrombosis in patients with cancer
2003
Regional Thrombolysis with Urokinase for Central Venous Catheter-related Thrombosis in Patients Undergoing High-dose Chemotherapy with Autologous Blood Stem Cell Rescue
1999
The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer
1995
Venous Thromboembolism and High Grade Gliomas
1993
Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia
2005
Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
1997
Tissue Factor Expression in Human Leukocytes and Tumor Cells
1995
Venous Thrombosis during Pregnancy: Leg and Trimester of Presentation
1992
Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study
1997
Efficacy and Safety of Oral Anticoagulation in Patients with Cancer
1997
Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments]
1993